Join the Camzyos group to help and get support from people like you.
Camzyos News
ESC: Mavacamten Cuts Need for Septal Reduction Tx with Hypertrophic Cardiomyopathy
TUESDAY, Aug. 29, 2023 – In patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), mavacamten reduces the need for septal reduction therapy (SRT) at week 56, according to a study...
FDA Approves Camzyos (mavacamten) for the Treatment of Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules)...
Ask a question
To post your own question to this support group, sign in or create an account.